about
Radiation-induced molecular changes in rat mammary tissue: possible implications for radiation-induced carcinogenesisOptimizing adjuvant therapy and survivorship care of stage III colon cancer.CAPOX associated with toxicities of higher grade but improved disease-free survival when compared with FOLFOX in the adjuvant treatment of stage III colon cancer.Circulating DNA Demonstrates Convergent Evolution and Common Resistance Mechanisms during Treatment of Colorectal Cancer.Current companion diagnostics in advanced colorectal cancer; getting a bigger and better piece of the piePlatelet "first responders" in wound response, cancer, and metastasis.Epigenetic dysregulation underlies radiation-induced transgenerational genome instability in vivo.Impact of Travel Distance and Urban-Rural Status on the Multidisciplinary Management of Rectal Cancer.Recent developments in the treatment of metastatic colorectal cancer.Sex-specific microRNAome deregulation in the shielded bystander spleen of cranially exposed mice.Genomic landscape of cell-free DNA in patients with colorectal cancer.Why a One Size Fits All Approach to RAS Might Not Fit Colorectal Cancer.Molecular characterisation of metastatic pancreatic neuroendocrine tumours (PNETs) using whole genome and transcriptome sequencing.Classifying colorectal cancer by tumor location rather than sidedness highlights a continuum in mutation profiles and Consensus Molecular Subtypes.Real-World Effect of Maintenance and Intermittent Chemotherapy on Survival in Metastatic Colorectal Cancer.Accelerating Therapeutic Development through Innovative Trial Design in Colorectal Cancer.Correction to: Accelerating Therapeutic Development through Innovative Trial Design in Colorectal Cancer.Effect of Adjuvant Chemotherapy on Stage II Rectal Cancer Outcomes After Preoperative Short-Course Radiotherapy.Impact of Postoperative Adjuvant Chemotherapy Following Long-course Chemoradiotherapy in Stage II Rectal Cancer.Cranial magnetic resonance imaging findings of leptomeningeal contrast enhancement after pediatric posterior fossa tumor resection and its significance.Report from the 19th annual Western Canadian Gastrointestinal Cancer Consensus Conference; Winnipeg, Manitoba; 29-30 September 2017Clinical application of cfDNA: moving in the right direction, but still a long way to goClinical, Pathological, and Molecular Characteristics of CpG Island Methylator Phenotype in Colorectal Cancer: A Systematic Review and Meta-analysisGenomic characterization of a well-differentiated grade 3 pancreatic neuroendocrine tumor.In vivo bystander effect: cranial X-irradiation leads to elevated DNA damage, altered cellular proliferation and apoptosis, and increased p53 levels in shielded spleenIrradiation induces DNA damage and modulates epigenetic effectors in distant bystander tissue in vivoExpression and prognostic significance of Oct2 and Bob1 in multiple myeloma: implications for targeted therapeuticsRetrospective comparison of CAPOX and FOLFOX dose intensity, toxicity, and clinical outcomes in the treatment of metastatic colon cancerSurvival Impact of CAPOX Versus FOLFOX in the Adjuvant Treatment of Stage III Colon CancerLeukocytoclastic vasculitis following lenalidomide during the treatment of follicular lymphomaMolecular Landscape of ERBB2/ERBB3 Mutated Colorectal CancerUntying the gordion knot of targeting MET in cancerDeleterious Effect of RAS and Evolutionary High-risk TP53 Double Mutation in Colorectal Liver MetastasesPrognostic Implications of Mucinous Differentiation in Metastatic Colorectal Carcinoma Can Be Explained by Distinct Molecular and Clinicopathologic CharacteristicsMechanisms of Innate and Acquired Resistance to Anti-EGFR Therapy: A Review of Current Knowledge with a Focus on Rechallenge TherapiesClinical and molecular characterization of early-onset colorectal cancerDisparity of Race Reporting and Representation in Clinical Trials Leading to Cancer Drug Approvals From 2008 to 2018Anti-EGFR-resistant clones decay exponentially after progression: implications for anti-EGFR re-challengeOutcomes and Characteristics of Patients Receiving Second-line Therapy for Advanced Pancreatic CancerEndogenous retrovirus transcript levels are associated with immunogenic signatures in multiple metastatic cancer types
P50
Q28577758-34823754-CBCC-439B-844F-73E4266B026FQ30249616-44A1E6BC-F3D0-4396-99B6-88B79C2EA29DQ38196043-3A4B1E1E-0E3B-4B72-B163-16107598466CQ38375059-EC8C575D-4CD8-4193-B441-86B75DD9E457Q39172118-B4BD78D5-FDC3-491A-98F5-4605167D1175Q39449769-A95B2E66-5631-498A-8768-9554BFCCC02EQ40289431-195F6882-A45E-4479-8C52-8F7775790BFCQ40411227-CC1A9949-0016-4CC0-A27C-BD63FF49F1AFQ41105389-89123CF5-0D87-43CA-B0E2-B069220D4ED4Q44051872-DC30FF95-8631-421A-ACA2-4C5D28B68141Q46334692-29BB7395-4AAC-4233-B6F1-C36E3F10F355Q47221065-F76F16D4-186D-498F-BBAA-D400104695AEQ48380432-352D9070-AF78-460D-A086-8EE8F227D05FQ49586760-EB4E0AD3-6ECC-4D6B-9CA3-70D7D4792969Q49887567-AE5585F8-88A0-4186-81E5-0D46B2F9EABDQ52371842-464D18B8-7E78-4E7C-9652-6D5700B24949Q52568022-DE2D70F3-CA80-40BF-9FB1-0944828BFD4DQ53088503-2EA09A9A-2664-41C1-B1E6-6E174EE5D7DBQ54321829-11E8ACB7-D023-45B8-B8E0-28E46AC0CA7CQ55464003-4CC950DE-A8E8-4EFA-A5AD-9986EBE81C08Q58783248-D65F8DE9-8208-4260-AFC3-288796209F20Q59133172-BAFA16C6-B68B-4A79-A32B-81B0D89A7522Q64123101-3161366E-81BA-490F-8D6E-4362303F6FDFQ64984088-C9A049BA-9BB8-4058-B3DF-C10ABFF90A08Q80518661-DFEDA5B2-8D2F-448A-9906-1688B09E05A4Q82799816-0FA1787E-FEDA-4AE5-96F2-3B3DC932F6C1Q83717357-370F6EC6-5DC3-4B27-AE87-B4BE5CC3FB42Q87065902-342DE83A-1EDD-426A-B153-A2ABBF0AE4EFQ87899531-C067FB33-20F4-4313-A9F9-8DAFD254F56CQ88194506-23EE3044-8195-4B00-8477-5B293DC7F42BQ88541726-C1BCAA38-7F26-4EC7-B8B0-1D7C9D87D38BQ88579911-4C7562A4-656F-4382-84F1-67D284B3192EQ88661079-4865220C-06FA-4667-82D7-852050BF26A8Q91391239-6114F50F-C9F1-4F8C-A865-3B98A2ADB5C0Q91528166-05CB920D-7D00-4E7F-8BB2-89ABE4D7997AQ92259250-D9BE953D-CFC2-466E-A9F7-A7FE982BD50DQ92635802-49ADBB22-19B0-4332-BBD0-5865CA7C3BCFQ93270142-6822BA54-4656-4755-ADCF-26D7B13825E6Q93385127-E194BCFD-60FB-4248-83D5-79303B2D8F0BQ96229503-3A0B5331-F3B0-43DC-8C6E-5E0DBA0BB6BA
P50
description
onderzoeker
@nl
researcher, ORCID id # 0000-0001-8189-2132
@en
name
Jonathan M Loree
@ast
Jonathan M Loree
@en
Jonathan M Loree
@es
Jonathan M Loree
@nl
type
label
Jonathan M Loree
@ast
Jonathan M Loree
@en
Jonathan M Loree
@es
Jonathan M Loree
@nl
prefLabel
Jonathan M Loree
@ast
Jonathan M Loree
@en
Jonathan M Loree
@es
Jonathan M Loree
@nl
P106
P21
P31
P496
0000-0001-8189-2132